This point mutation also renders a constitutive activation of KRAS [32], In the near future, it would be important to analyze possible spontaneous mutations in any other CRC cell line used as experimental model to study the molecular mechanisms of therapy-resistance or new drug development. Here, KRAS is linked to colorectal carcinoma.